[(18)F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy.

Details

Ressource 1Download: 26984385_BIB_7EB4C9B21B02.pdf (822.01 [Ko])
State: Public
Version: Final published version
Serval ID
serval:BIB_7EB4C9B21B02
Type
Article: article from journal or magazin.
Collection
Publications
Title
[(18)F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy.
Journal
Radiation oncology
Author(s)
Herrera F.G., Breuneval T., Prior J.O., Bourhis J., Ozsahin M.
ISSN
1748-717X (Electronic)
ISSN-L
1748-717X
Publication state
Published
Issued date
16/03/2016
Peer-reviewed
Oui
Volume
11
Pages
43
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
To compare the prognostic value of different anatomical and functional metabolic parameters determined using [(18)F]FDG-PET/CT with other clinical and pathological prognostic parameters in cervical cancer (CC).
Thirty-eight patients treated with standard curative doses of chemo-radiotherapy (CRT) underwent pre- and post-therapy [(18)F]FDG-PET/CT. [(18)F]FDG-PET/CT parameters including mean tumor standardized uptake values (SUV), metabolic tumor volume (MTV) and tumor glycolytic volume (TGV) were measured before the start of CRT. The post-treatment tumor metabolic response was evaluated. These parameters were compared to other clinical prognostic factors. Survival curves were estimated by using the Kaplan-Meier method. Cox regression analysis was performed to determine the independent contribution of each prognostic factor.
After 37 months of median follow-up (range, 12-106), overall survival (OS) was 71 % [95 % confidence interval (CI), 54-88], disease-free survival (DFS) 61 % [95 % CI, 44-78] and loco-regional control (LRC) 76 % [95 % CI, 62-90]. In univariate analyses the [(18)F]FDG-PET/CT parameters unfavorably influencing OS, DFS and LRC were pre-treatment TGV-cutoff ≥562 (37 vs. 76 %, p = 0.01; 33 vs. 70 %, p = 0.002; and 55 vs. 83 %, p = 0.005, respectively), mean pre-treatment tumor SUV cutoff ≥5 (57 vs. 86 %, p = 0.03; 36 vs. 88 %, p = 0.004; 65 vs. 88 %, p = 0.04, respectively) and a partial tumor metabolic response after treatment (9 vs. 29 %, p = 0.0008; 0 vs. 83 %, p < 0.0001; 22 vs. 96 %, p < 0.0001, respectively). After multivariate analyses a partial tumor metabolic response after treatment remained as an independent prognostic factor unfavorably influencing DFS and LRC (RR 1:7.7, p < 0.0001, and RR 1:22.6, p = 0.0003, respectively) while the pre-treatment TGV-cutoff ≥562 negatively influenced OS and DFS (RR 1:2, p = 0.03, and RR 1:2.75, p = 0.05).
Parameters capturing the pre-treatment glycolytic volume and metabolic activity of [(18)F]FDG-positive disease provide important prognostic information in patients with CC treated with CRT. The post-therapy [(18)F]FDG-PET/CT uptake (partial tumor metabolic response) is predictive of disease outcome.

Keywords
Adult, Aged, Aged, 80 and over, Chemoradiotherapy, Cisplatin/therapeutic use, Disease-Free Survival, Female, Fluorodeoxyglucose F18, Follow-Up Studies, Glycolysis, Humans, Kaplan-Meier Estimate, Middle Aged, Multimodal Imaging, Multivariate Analysis, Positron-Emission Tomography, Prognosis, Proportional Hazards Models, Tomography, X-Ray Computed, Treatment Outcome, Uterine Cervical Neoplasms/drug therapy, Uterine Cervical Neoplasms/radiotherapy, Cervical cancer, Chemo-radiotherapy, Standard uptake value, Tumor glycolytic volume, [18F]FDG-PET/CT
Pubmed
Web of science
Open Access
Yes
Create date
29/01/2015 20:20
Last modification date
20/08/2019 14:39
Usage data